JEE Main · 2023easyCORD-060

To inhibit the growth of tumours, identify the compounds used from the following: (A) EDTA (B) Coordination Compounds…

Coordination Compounds · Class 12 · JEE Main Previous Year Question

Question

To inhibit the growth of tumours, identify the compounds used from the following: (A) EDTA (B) Coordination Compounds of Pt (C) D-Penicillamine (D) Cis-Platin

Options
  1. a

    B and D Only

  2. b

    C and D Only

  3. c

    A and B Only

  4. d

    A and C Only

Correct Answera

B and D Only

Detailed Solution

🧠 Tumour Drugs Are Pt-Based

Anticancer chemotherapy in coordination chemistry comes down to platinum complexes. The flagship drug is cis-platin (cis\mathrm{cis}-[Pt(NH3)2Cl2][\mathrm{Pt(NH_3)_2Cl_2}]); the broader class is "coordination compounds of Pt" (carboplatin, oxaliplatin, etc.).

EDTA and D-penicillamine are chelating drugs, used in heavy-metal poisoning (Pb and Cu respectively) — not anticancer.

🗺️ Tag Each

(A) EDTA — lead-poisoning chelator. Not antitumour. (B) Coordination compounds of Pt — anti-tumour. ✓ (C) D-penicillamine — Wilson's-disease (Cu) chelator. Not antitumour. (D) Cis-platin — the canonical antitumour Pt complex. ✓

So B and D — option (1).

The "Pt = Cancer" Anchor

Whenever a JEE option says "X is used in cancer treatment", check: is X a Pt complex? If yes, almost always correct. The Pt-based family (cisplatin, carboplatin, oxaliplatin, nedaplatin) treats roughly 50% of all chemotherapy regimens worldwide.

⚠️ D-Penicillamine ≠ Anticancer

Some students remember that D-penicillamine is "used in chelation therapy" and lump it with "treats serious diseases → cancer". Wrong specificity: D-penicillamine treats Wilson's disease (Cu accumulation) and rheumatoid arthritis, not tumours.

Answer: (1) B and D Only\boxed{\text{Answer: (1) B and D Only}}

Practice this question with progress tracking

Want timed practice with adaptive difficulty? Solve this question (and hundreds more from Coordination Compounds) inside The Crucible, our adaptive practice platform.